Drug Evaluation Committee Slide presentation "Shaping the Ideas of Pharmaceutical Companies: Challenges in Delivering Appropriate Drug Information to Patients" (October 13, 2025, 58th Annual Meeting of the Japanese Pharmaceutical Manufacturers Association)
Pharmacovigilance Subcommittee
October 2025
This document consists of lecture slides at the following symposium.
The 58th Annual Meeting of the Japanese Pharmaceutical Association
Section Meeting 16 Joint Section Meeting of the Japanese Pharmaceutical Association and PMDA: Let's make more use of Drug Information
With the diversification of drug discovery modalities such as cell therapy and gene therapy, the provision of drug information has become increasingly important for appropriate treatment selection and patient safety. To this end, pharmaceutical companies are creating and providing a variety of materials and applications tailored to the characteristics of their drugs, including "RMP materials" based on drug risk management plans, alerts regarding adverse drug reactions, instructions for use of drug formulations, and symptom management tools.
In this context, there is an urgent need for medical professionals to collect up-to-date and accurate information and provide it to patients, as well as to establish an environment in which patients themselves can access appropriate information. To this end, it is important to listen to the voices of patients and strengthen cooperation among relevant stakeholders, including government, medical professionals, and businesses. In this symposium, we presented "differences in information needs according to patients' disease characteristics and treatment stages" and "examples of RMP materials created in collaboration with patient groups," and discussed (1) issues to make the materials themselves easier to use and (2) issues for pharmacists in providing medication guidance together.
Deliverables of the Drug Evaluation Committee Return to list of all deliverables